Study identifier:D9120C00027
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Validation of patient-reported outcomes measures for the assessment of GERD symptoms and their subsequent impact on patients with partial response to Proton Pump Inhibitor (PPI) treatment in a two part multi-center phase IIa study including a four week randomised, double-blind, placebo-controlled, parallel-group treatment period
GERD
Phase 2
No
AZD3355, Placebo, Gelusil®
All
478
Interventional
18 Years - 70 Years
Allocation: Randomized
Endpoint Classification: N/A
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Other
Verified 01 Dec 2014 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
This research study is being done to gather information about how to do further clinical studies using AZD3355 as an add-on treatment to proton pump inhibitors (PPI).
Location
Location
AKRON, OH, United States
Location
ANAHEIM, CA, United States
Location
ANDERSON, SC, United States
Location
ARKANSAS CITY, KS, United States
Location
ASHEVILLE, NC, United States
Location
ATHENS, AL, United States
Location
ATLANTA, GA, United States
Location
BALTIMORE, MD, United States
Arms | Assigned Interventions |
---|---|
Experimental: AZD3355 | Drug: AZD3355 Immediate Release capsule administered as a single dose, 65mg, twice daily for 4 weeks Other Name: Lesogaberan Drug: Gelusil® Chewable tablets taken as needed Other Name: Gelusil® |
Placebo Comparator: Placebo | Drug: Placebo capsule. administered as a single dose twice daily for 4 weeks Drug: Gelusil® Chewable tablets taken as needed Other Name: Gelusil® |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.